Loading...
XNAS
BRKR
Market cap7.29bUSD
Dec 05, Last price  
48.03USD
1D
-0.72%
1Q
55.79%
Jan 2017
126.77%
IPO
101.13%
Name

Bruker Corp

Chart & Performance

D1W1MN
XNAS:BRKR chart
P/E
64.42
P/S
2.16
EPS
0.75
Div Yield, %
0.31%
Shrs. gr., 5y
-0.92%
Rev. gr., 5y
10.19%
Revenues
3.37b
+13.56%
297,569,000435,834,000547,576,0001,107,100,0001,114,500,0001,304,900,0001,651,700,0001,791,400,0001,839,400,0001,808,900,0001,623,800,0001,611,300,0001,765,900,0001,895,600,0002,072,600,0001,987,500,0002,417,900,0002,530,700,0002,964,500,0003,366,400,000
Net income
113m
-73.53%
3,646,00018,481,00031,529,00064,900,00081,200,00095,400,00092,300,00077,500,00080,100,00056,700,000101,600,000153,600,00078,600,000179,700,000197,200,000157,800,000277,100,000296,600,000427,200,000113,100,000
CFO
251m
-28.22%
42,193,00037,693,00028,209,000106,900,000149,800,000156,100,00087,700,000133,100,000145,000,000114,300,000229,200,000130,800,000154,400,000239,700,000213,400,000333,200,000282,400,000262,000,000350,100,000251,300,000
Dividend
Aug 30, 20240.05 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
IPO date
Aug 04, 2000
Employees
8,525
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT